United States-based Akero Therapeutics Inc. (Nasdaq: AKRO), has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for efruxifermin (EFX), an investigational FGF21 analogue, intended for the treatment of non-alcoholic steatohepatitis (NASH), a non-alcoholic fatty liver disease, it was reported on Friday.
The product was granted the designation based on the positive efficacy data recently reported from the company's Phase 2a BALANCED study.
The firm is planning to start a Phase 2b/3 adaptive trial of EFX in biopsy-confirmed NASH patients in the first half of 2021, based on guidance received from the United States Food and Drug Administration (FDA).
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Alvotech and Teva secure US launch date for Eylea biosimilar AVT06
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion